Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 13, 2007 Rich Duprey	Chattem Has Relief on the Way The consumer products company has a portfolio of new products to drive revenues and profits. Investors, take note.
The Motley Fool March 26, 2007 Rich Duprey	Breaking Chattem's Bond The consumer-products company should continue to give shareholders that soothing feeling.
The Motley Fool September 27, 2007 Ryan Fuhrmann	Chattem Chugs Along Shares of Chattem hit a new high today on solid results, and management ups its guidance, but what does that mean going forward? Investors should take note.
The Motley Fool September 26, 2007 Ryan Fuhrmann	Foolish Forecast: Will Chattem's Recent Results Prove Soothing? In advance of earnings reports at the health-care and consumer-products firm, analysts are projecting 47% year-over-year growth due to recently acquired brands.
The Motley Fool July 10, 2006 Stephen D. Simpson	Chattem Holds Its Ground Management seems to have more faith in this consumer-goods company's business than Wall Street does. It is likely not a stock for the faint of heart.
The Motley Fool December 22, 2009 Brian Orelli	This Acquisition Is Icy Hot Expensive price, but Chattem may still be a good buy for sanofi-aventis.
The Motley Fool October 11, 2006 Brian Lawler	Monopoly Woes Help Chattem Grow Acquisitions boost the health-care brand owner's shares to new highs.
The Motley Fool September 17, 2004 David Meier	Gettin' Funky With Chattem Is Chattem good enough for your portfolio?
The Motley Fool July 12, 2007 Jeremy MacNealy	Fool on Call: Chattem Looks Toward a Record '08 Timely acquisitions and cost savings add up to a big year for this consumer-goods producer. Prospective investors should at least take a closer look.
The Motley Fool July 11, 2007 Brian Orelli	Icy Hot Results From Chattem The manufacturer of over-the-counter health-care products sees a huge increase in sales, but can it last? Investors, take note.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool April 17, 2006 Stephen D. Simpson	Chattin' Up Chattem Great brands owned by a boring and unknown company. Might there be value afoot for investors?
The Motley Fool September 20, 2005 Jeremy MacNealy	Chattem's Icy Hot Stock The stock of this manufacturer of over-the-counter health-care products is on an exceptional run. Shareholders may be wondering whether this is a good time to take some money off the table.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool September 11, 2010 Anand Chokkavelu	How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool October 26, 2011	A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
The Motley Fool June 20, 2005 Matt Thurmond	Chattem's High-Dollar Brands Health-care product maker generates big bucks from the body's annoying little problems.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool October 13, 2008 Brian Orelli	Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool October 17, 2006 Brian Lawler	See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note.
The Motley Fool July 18, 2006 Stephen D. Simpson	Can J&J Do Better Than GDP? Investors and analysts are obsessed with growth, but Johnson & Johnson isn't.
The Motley Fool December 18, 2008 Selena Maranjian	Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool February 8, 2006 Nathan Slaughter	Best Blue Chip: Johnson & Johnson In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: it is easy to see why Johnson & Johnson, deserves to carry home the gold.
The Motley Fool February 22, 2010 Brian Orelli	A Huge Business Wrapped Up in Tiny Packages Drug investors shouldn't forget about over-the-counter products.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool August 14, 2007 Brian Orelli	A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.